# Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

> **NCT05269290** · PHASE3 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 240 (actual)

## Conditions studied

- Influenza, Human
- Acute Respiratory Infection
- Common Cold

## Interventions

- **DRUG:** Ingavirin®, syrup, 30 mg/5 ml
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05269290
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-23
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-07-15
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269290, "Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05269290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*